Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen BA104R02

$887.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen, recombinant
Suitable for detection of IgA, IgG & IgM antibodies in ELISA
Lot specific concentration, specified in mg/mL
1 mg

SKU: BA104R02 Category: Infectious disease proteins Tags: antigen, Varicella-Zoster Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Varicella Zoster Virus (VZV) Envelope Glycoprotein E
species reactivity	Varicella-Zoster Virus
applications	ELISA
assay type	Indirect & quantitative
available size	1 mg

Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen BA104R02

kit
Research area Infectious Disease
Storage Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Form liquid
Associated products Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen (BA104R02) Varicella-Zoster Virus Antigen (BA104VS) Varicella-Zoster Virus Glycoprotein Antigen (BA104VSG) Varicella-Zoster Virus IgA Control Serum (BC104A) Varicella-Zoster Virus IgG Control Serum (BC104G) Varicella-Zoster Virus IgM Control Serum (BC104M) Varicella-Zoster Virus IgA ELISA Kit (ESR104A) Varicella-Zoster Virus IgG ELISA Kit (ESR104G) Varicella-Zoster Virus IgM ELISA Kit (ESR104M)

target relevance
Varicella-ZosterVirus
Description Virus that causes chickenpox (varicella) and shingles (herpes zoster)
Structure Varicella-zoster virus (VZV), also known as Human herpesvirus 3 (HHV-3), is an enveloped, double-stranded DNA virus belonging to the genus Varicellovirus within the family Herpesviridae. The viral genome is enclosed within an icosahedral capsid surrounded by a protein tegument and a lipid envelope containing multiple glycoproteins that mediate host cell attachment and entry. Humans are the only known natural reservoir of the virus. Primary infection results in varicella (chickenpox), after which the virus establishes lifelong latency within sensory nerve ganglia. Reactivation of latent virus later in life results in herpes zoster (shingles). Varicella-zoster virus is highly contagious and spreads primarily through respiratory droplets, aerosolized virus from skin lesions, and direct contact with vesicular fluid.
Diagnosis The diagnosis of varicella-zoster virus infection is performed through clinical evaluation, molecular testing, and serological methods. Polymerase chain reaction (PCR) is the preferred laboratory method due to its high sensitivity and specificity and can detect VZV DNA in vesicular fluid, lesion swabs, cerebrospinal fluid, blood, and tissue specimens. Direct fluorescent antibody testing and viral culture may also be used but are less sensitive than PCR. Serological assays, including ELISA-based tests, can detect VZV-specific IgM and IgG antibodies and are useful for determining immune status, previous exposure, or vaccine response. Laboratory confirmation is particularly important in atypical cases, immunocompromised patients, and individuals with suspected neurological complications.
Symptoms Primary infection with varicella-zoster virus typically develops after an incubation period of approximately ten to twenty-one days and presents as chickenpox, characterized by fever, malaise, headache, and a generalized pruritic vesicular rash that progresses through macular, papular, vesicular, and crusting stages. Following recovery, the virus remains latent in sensory ganglia and may reactivate years or decades later as shingles. Herpes zoster is characterized by painful, unilateral vesicular eruptions distributed along affected dermatomes and is often preceded by burning, tingling, or localized pain. Complications of VZV infection include secondary bacterial skin infections, pneumonia, encephalitis, meningitis, cerebellitis, vision-threatening ophthalmic zoster, and postherpetic neuralgia, a chronic pain syndrome that may persist long after skin lesions have resolved. Severe disease is more common in elderly individuals, pregnant women, newborns, and immunocompromised patients.

Data

FAQ & Publications

Frequently Asked Questions

What is the recommended storage condition for the Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen BA104R02?

The recommended storage condition for the VZV Envelope Glycoprotein E Control Antigen BA104R02 is at -65°C. It is important to avoid freeze/thaw cycles and to sonicate the antigen before use to ensure optimal performance.

For which antibody isotypes is the Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen BA104R02 suitable for detection in ELISA assays?

This control antigen is suitable for the detection of IgA, IgG, and IgM antibodies in ELISA assays, facilitating indirect and quantitative measurement of immune response to Varicella Zoster Virus Envelope Glycoprotein E.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.